PCI Pharma Services announces multi-million expansion of UK manufacturing facility

The CDMO will add two new facilities to support its high potency manufacturing services

The Contract Development and Manufacturing Organisation (CDMO) will add two new facilities dedicated to the manufacturing and packaging of solid oral-dose tablets and capsules to the site.  

A contained manufacturing building (CMF2) will double large-scale processing capacity including dispensing and fluid bed granulation of high-potency solid-dose products at commercial scale. This is based on the company’s original CMF1, which opened in 2013. PCI will also launch a new high-potency, multi-product packaging facility with primary and secondary blistering and bottling suites.  

Speaking about the news, PCI Pharma Services CEO Salim Haffar said the expansion would ‘address the growing and urgent need for specialty global manufacturing services within the oncology arena.’  

‘As the market expands for potent therapies and highly complex, concentrated formulations that can present unique challenges to manufacturing and packaging, we’re proud to be one of the few providers with the global capabilities to manage this specialty at both clinical and importantly, commercial scale,’ he said.  

Both facilities will contain state-of-the-art equipment, including a replica of CMF1’s large-scale granulation suite and a down-flow booth with containment screening. 

The expansion is expected to create up to 40 new jobs in the first year and more as the facilities scale up. PCI currently employs close to 500 people at the Tredegar site.